MedTrace Logo

An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer

NCT00291122 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2008-09-16

No results posted yet for this study

Summary

To assess the quantitative real time PCR results results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors of indicators of response to celecoxib.

Conditions

Interventions

DRUG

celecoxib 400 mg BID

Sponsors & Collaborators

  • University of Kansas

    lead OTHER

Principal Investigators

  • Carol J Fabian, MD · University of Kansas Medical Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291122 on ClinicalTrials.gov